Biotech Stocks At 52-Week Highs - PGEN, EXEL, TWST, HNGE, PBYI
On September 30, 2026, biotech stocks PGEN, EXEL, TWST, HNGE, and PBYI hit 52-week highs. PGEN rose 6% to $9.98, EXEL reached $61.14, TWST climbed 3% to $197.19, HNGE hit $98.41, and PBYI touched $10.10. Key catalysts included clinical trial results, FDA designations, and revenue growth.
How this was made
The 30-second read
Why it matters
Collective positive news reinforces a bullish bias for the biotech sector, but individual stock risk remains tied to trial outcomes and execution of acquisitions.
Market read
Each company’s fresh catalyst contributed to a day‑wide rally in biotech equities, suggesting short‑term buying opportunities but with company‑specific risk.
What to watch
Liquidity constraints in small‑cap biotech and the need for further data readouts could temper upside.
Background
The article aggregates several biotech companies that each reached 52‑week highs on the same day, highlighting recent clinical, regulatory, and partnership developments.
Ticker impact
Precigen hit a 52‑week high of $9.98, up 6% after announcing FDA platform designation and HPV trial progress.
upward pressure as investors price in trial momentum
FDA platform designation and advancing Phase 2 studies are material catalysts for a commercial‑stage biotech.
Exelixis reached a new 52‑week high of $61.14 following Q2 profit beat and strong CABOMETYX sales.
upward bias as momentum from earnings persists
Quarterly profit beat and robust product sales are fresh, material information for the stock.
Twist Bioscience rose over 3% to a 52‑week high of $197.19 after announcing a collaboration with Eli Lilly’s TuneLab for AI‑driven antibody discovery.
upward pressure from partnership news
Collaboration with Eli Lilly is a concrete catalyst likely to boost revenue expectations.
Hinge Health hit a 52‑week high of $98.41, up on strong Q2 revenue growth and the announced acquisition of Cylinder Health for $105 million.
upward bias as acquisition synergies are priced in
The cash acquisition is a material corporate action that can enhance future earnings.
Puma Biotechnology reached a 52‑week high of $10.10 after reporting licensing of Neratinib and ongoing Phase 2 ALISCA‑Lung2 trial activity.
upward pressure as investors react to trial and licensing news
New trial data and drug licensing are fresh, material developments for a biotech.
Market effects
Biotech sector gains from multiple companies reporting strong trial and partnership news, supporting sector momentum.
U.S. biotech equities see broad uplift, potentially lifting related ETFs.
Positive biotech catalysts may attract foreign investor interest in the sector.
Counterpoint
Recent price spikes may be overbought; investors should watch for trial setbacks or regulatory delays.
Key entities
- companyPrecigen Inc.
Biopharma advancing HPV‑targeted therapies.
- companyExelixis Inc.
Oncology drug developer.
- companyTwist Bioscience Corp.
DNA synthesis and biotech services.
- companyHinge Health Inc.
Digital musculoskeletal health platform.
- companyPuma Biotechnology Inc.
Cancer drug developer.
